Science Team
Richard Brody, Ph.D.
Protein Biochemistry
Dr. Brody is a protein biochemist with more than 25 years of experience directing laboratory programs in biotechnology. In 2006, Dr. Brody co-founded Applied Biomolecular Technologies, a company that provides research and development services for the production, purification, characterization, and formulation of antibodies and other proteins. Dr. Brody’s previous position was as Biochemistry Research Leader at Battelle where he directed and managed research and development programs in protein biochemistry for both industrial and government clients.
Dr. Brody received his bachelors degree from Cornell, his Ph.D. from Harvard, and did his postdoctoral work at The Ohio State University.
Dr. Brody contributes to Enlyton’s R&D efforts in the design, production, purification, characterization, and modification of antibody products.
Nathan C. Hall, MD, Ph.D.
Imaging Science
Dr. Hall is an Assistant Professor and Division Chief of Nuclear Medicine of the Department of Radiology at The Ohio State University (OSU). Dr. Hall will develop pre-clinical and clinical imaging protocols for validation of the effectiveness for use of the PET tracer for PET/CT procedures. Dr. Hall is currently exploring new uses of molecular imaging to guide and follow response to therapy in oncology.
Dr Hall holds a degree in Medicine from the University of Cincinnati Medical Center (Cincinnati, OH) and a Ph.D. in Chemistry from the University of Kentucky (Lexington, KY). His specialty training is in Nuclear Medicine at the University of Tennessee (Knoxville, TN).
Dr. Hall oversees all imaging research for Enlyton.
George H. Hinkle, MS, RPh
Radiopharmaceutical Science
Mr. Hinkle is an Associate Professor of Pharmacy and Radiology at The Ohio State University (OSU). He has more than 25 years experience in radiopharmaceutical research/development primarily with radiolabeled antibodies and small molecules for tumor targeting. Mr. Hinkle has experience in leading clinical trials involving radiopharmaceuticals and will coordinate the laboratory development, pre-clinical chemistry and animal imaging of radiolabeled compounds using MicroPET/CT and tissue distribution/pharmacokinetic studies.
Mr. Hinkle holds a degree in Pharmacy and a masters degree in Nuclear Pharmacy, both from Purdue University (West Lafayette, IN)
Mr. Hinkle provides expertise in the clinical use of radiopharmaceutical agents, as Enlyton moves radiolabeled compounds into the clinical testing stages.
Charles L. Hitchcock, MD, Ph.D., FACP
Pathology
Dr. Hitchcock is an Associate Professor-Clinical of Pathology at The Ohio State University (OSU). He has more than 25 years experience with the application of imaging and cytometric technologies to assessing cancer biology. Dr. Hitchcock’s research has centered on improving patient survival by combining imaging with pathology to detect cancer. Since returning to OSU in 1993, he has worked with Dr. Edward W. Martin, Jr. and the other members of Enlyton team providing pathology expertise to various oncology projects.
Dr Hitchcock holds a degree in Medicine and completed his Ph.D. in Anatomy, both at OSU (Columbus, OH). His specialty training includes a Residency in Anatomical and Clinical Pathology at Shands Teaching Hospital, University of Florida (Gainesville, FL) and a Surgical Pathology Fellowship at the University of South Florida (Tampa, FL).
Dr Hitchcock provides Enlyton with expertise in pathology.
Ergun Kocak, MD
Immunology and Therapy
Dr. Kocak is an Assistant Professor in the Division of Plastic and Reconstructive Surgery at The Ohio State University (OSU). He has conducted clinical and basic science research in the areas of surgical oncology and plastic surgery. Dr. Kocak’s basic science research focused on developing monoclonal antibodies that could be used to modulate immune responses against cancer. He has been the co-investigator of a NIH-funded project that utilized state of the art imaging and intraoperative navigation systems to facilitate the identification and resection of recurrent colon cancer. He is currently engaged in research focusing on utilizing plastic surgical tissue transfer techniques as a modality for targeting anti-cancer therapies.
Dr. Kocak holds a degree in Medicine from OSU (Columbus, OH). He completed his surgery training in plastic surgery at OSU (Columbus, OH). Dr. Kocak completed fellowship training at MD Anderson Cancer Center (Houston, TX) where he specialized in microsurgery for the reconstruction of complex defects that result from cancer resections. Dr. Kocak leads investigation of Enlyton’s new molecules for targeted drug delivery.
Cathy M. Mojzisik, RN, MS
Clinical Operations
Ms. Mojzisik is a Senior Research Nurse for the The Ohio State University (OSU) Department of Radiology. Her oncologic clinical research experience of over 30 years includes radiolabeled antibodies for imaging, intraoperative, and therapeutic applications. Clinical research experience includes 15 years in the pharmaceutical industry including project management and on-site monitoring.
Ms. Mojzisik holds a Bachelor of Science in Nursing from St. John College of Cleveland (Cleveland, OH) and a Masters of Science degree from the College of Nursing at OSU (Columbus, OH).
Ms. Mojzisik provides expertise in the planning, implementation, and execution of clinical trials.
Stephen P. Povoski, MD, FACS
Surgical Oncology
Dr. Povoski is an Associate Professor of Surgery at The Ohio State University (OSU) and an Attending Surgical Oncologist at the Arthur G. James Cancer Hospital. His clinical practice focuses upon breast cancer, including special interests in sentinel lymph node mapping and biopsy technology, image-guided minimally invasive breast biopsy technology, and the development and refinement of breast cancer imaging, detection, and therapy technologies. Dr. Povoski has specific clinical research interests in developing innovative strategies for perioperative and intraoperative tumor imaging and detection and in developing tumor-directed surgical and non-surgical therapies, as they relate to many different solid malignancies.
Dr. Povoski holds a Bachelors degree in Biological Sciences (summa cum laude) from the State University of New York (SUNY) at Buffalo (Buffalo, NY). Dr. Povoski holds a degree in Medicine (summa cum laude) from the SUNY Health Science Center at Syracuse (Syracuse, NY). Dr. Povoski completed his general surgery training at the University of Cincinnati Medical Center (Cincinnati, OH). Dr. Povoski completed fellowship speciality training in a Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center (New York, NY).
Dr. Povoski provides expertise in the surgical aspects of cancer imaging, detection, and therapy.
Vish V. Subramaniam, Ph.D.
Applied Physics
Dr. Subramaniam is a Professor, Department of Mechanical Engineering and Chemical Physics Program, The Ohio State University (OSU). Dr. Subramaniam is interested in electromagnetic methods for intraoperative detection and localized imaging of cancer.
Dr. Subramaniam earned his Ph.D. degree from Carnegie Mellon University (Pittsburgh, PA).
Dr. Subramaniam coordinates development of markers for imaging and detection, and serves as scientific advisor on cancer detection techniques and measurement systems.
Duxin Sun, Ph.D.
Pharmacokinetics
Dr. Sun is an Associate Professor of Pharmaceutics, College of Pharmacy, University of Michigan (Ann Arbor, MI). Dr. Sun has considerable experience in tumor targeting, cancer drug discovery and development, and pharmacokinetics.
Dr. Sun earned his Ph.D. degree in Pharmaceutic from the University of Michigan (Ann Arbor, MI).
Dr. Sun oversees use of the proposed PET Tracer in animal model experiments, and the conduct of associated immunogenicity and pharmacokinetics assays.
Ron X. Xu, Ph.D.
Biomedical Engineering
Dr. Xu is an Assistant Professor of Biomedical Engineering at The Ohio State University (OSU). Before joining OSU, Dr. Xu had previously been Director of Technology Development in a medical device company for five years and led the company efforts in technology development, benchtop testing, animal validation studies, and filing FDA 510k applications. His teaching and research interests include medical device design and innovation, multimodal intraoperative cancer detection, minimally invasive cancer imaging, and multifunctional theranostics. Dr. Xu has led the development and validation of multiple handheld devices for cancer detection and intraoperative imaging. Dr. Xu is an inventor/co-inventor of seven published patents and over a dozen provisional patents in the field of cancer imaging.
He earned his Ph.D. degree in Mechanical Engineering from Massachusetts Institute of Technology (Cambridge, MA), and this was followed by postdoctoral training at Stanford University (Palo Alto, CA).
Dr. Xu provides expertise in developing novel multifunctional agents for cancer targeting, multimodal imaging, and synergistic therapy.
Tom Zupancic, Ph.D.
Molecular Biology
Dr. Zupancic is a molecular biologist with extensive experience in the design and execution of applied biotechnology research programs in the areas of protein therapeutics and bioproduction systems, including the manipulation of gene expression and production of recombinant proteins in bacterial and mammalian systems. In 2006, Dr. Zupancic co-founded Applied Biomolecular Technologies (ABT), a company that provides research and development services for the production, purification, characterization, and formulation of antibodies and other proteins, and serves as their Chief Scientific Officer.
Dr. Zupancic received his bachelors degree from the Ohio State University, his Ph.D. from Indiana University Bloomington, is a former National Science Foundation Graduate Fellow, and holds 17 U.S. patents.
Dr. Zupancic contributes to Enlyton’s R&D efforts in the design and production of novel monoclonal antibodies and antibody fragments.